Insulet Corp - Company Profile

Powered by

All the sales intelligence you need on Insulet Corp in one solution.

$395 $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Insulet Corp fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Insulet Corp.

Back to companies

Insulet Corp: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Related keylists

Insulet Corp (Insulet) is a medical device company that develops, manufactures and distributes insulin management systems for diabetic patients. The company's major products include the Omnipod platform, which features the Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System, and the Classic Omnipod. Its insulin management system, OmniPod, is a continuous insulin delivery system for insulin-dependent diabetics. The OmniPod system consists of a disposable self- adhesive tubeless insulin infusion device and a handheld wireless device, Personal Diabetes Manager. The company also works in partnership with various biotechnology and pharmaceutical companies that use the customized form of its OmniPod system to deliver drugs at specified intervals at predetermined doses. The company markets its products directly and through distributors in the US, Canada, Israel, China, and the UK, among others. Insulet is headquartered in Acton, Massachusetts, the US.

 Gain a 360-degree view of Insulet Corp and make more informed decisions for your business Gain a 360-degree view of Insulet Corp and make more informed decisions for your business Learn more
Headquarters United States of America
Address 100 Nagog Park, Acton, Massachusetts, 01720-3440
Website www.omnipod.com
Telephone 1 978 6007000
No of Employees 5,400
Industry Medical Equipment
Ticker Symbol & Exchange PODD (NASD)
Revenue (2024) $2.7B 30.7% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ -40.9% (2024 vs 2023)
Market Cap* $11.4B
Net Profit Margin (2024) XYZ -54.8% (2024 vs 2023)
* As of and is in US$
View Insulet Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Insulet Corp premium industry data and analytics

40+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

6

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Insulet Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Omnipod 5 Omnipod
OmniPod Insulin Management System Omnipod Dash
OmniPod Insulin Delivery System Omnipod Display
XYZ
XYZ
XYZ
Understand Insulet Corp portfolio and identify potential areas for collaboration Understand Insulet Corp portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2025 Regulatory Approval In December, the company received FDA 510(k) clearance for enhancements to the Omnipod 5 Automated Insulin Delivery System.
2025 Contracts/Agreements In September, the company entered into a partnership with Pantone to create Omnipod Mango.
2025 New Products/Services In March, the company announced the launch of its Omnipod 5 Automated Insulin Delivery (AID) System in Australia.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters Insulet Corp DexCom Inc West Pharmaceutical Services Inc Tandem Diabetes Care Inc Debiotech SA
Headquarters United States of America United States of America United States of America United States of America Switzerland
City Acton San Diego Exton San Diego Lausanne
State/Province Massachusetts California Pennsylvania California Waadt
No. of Employees 5,400 11,000 10,800 2,500 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Ashley A. McEvoy Director; President; Chief Executive Officer Executive Board 2025 55
Flavia Pease Executive Vice President; Chief Financial Officer Senior Management 2025 53
Eric Benjamin Chief Operating Officer; Executive Vice President Senior Management 2023 43
Amit Guliani Senior Vice President; Chief Technology Officer Senior Management 2025 -
Trang Ly, Ph.D. Senior Vice President; Chief Medical Officer Senior Management 2024 -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Insulet Corp key executives to enhance your sales strategy Gain insight into Insulet Corp key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?